Telehealth — a new frontier in healthcare that seeks to apply the creature comforts of the digital age to medical services is a field that carries much promise. However, most telehealth stocks haven’t exactly been performing well as of late.There’s no big mystery as to why — the COVID-19 pandemic saw a sudden surge in utilization, but as soon as in-person healthcare services resumed, demand dried up significantly. On top of that, this is a field with no shortage of regulatory and legal risks — while the rap ...

Hims & Hers Health, Inc. (HIMS) has emerged as a transformative player in the personalized healthcare market, showcasing robust growth in 2024. Shares of the company have risen 43% in the past month, significantly outperforming the industry’s growth of 5.5%.In the third quarter, the company reported revenues of $401.6 million, reflecting a 77% year-over-year increase. Earnings per share (EPS) of 32 cents met the analyst expectations. The company now boasts over 2 million subscribers, of which more than 50% ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.Hims & Hers Health, Inc. (NYSE: HIMS ) is a San Francisco-based $6.7-billion market cap firm that provides a telehealth solution that links people with qualified doctors in the US, the UK, and throughoutHe leads the investing group Beyond the Wall In ...

Hims & Hers Health, Inc. (NYSE: HIMS ) stock is still substantially undervalued even after a massive YTD rally. A 35% discount looks extremely attractive because HIMS is a very promising business that successfully capitalizes on robust secular trendsComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies p ...

The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at Johns Hopkins University in Baltimore, Maryland, and also serves as the chief medical officer at Sesame, an online telehealth platform. As an avid supporter of telemedicine, his appointment as the FDA chief, upon Senate approval, would benefit telehealth companies and their stocks. Here are two telehealth stocks in th ...

Hims & Hers Health, Inc. (NYSE: HIMS ) leads the fast-growing health and wellness market using its technology-based platform to offer personalized, accessible care. The company has been a pioneer in subscription-based healthcare, driving substantial revenue and subscriberYiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certifi ...

Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.Shares of Hims & Hers (HIMS 0.61%) jumped as much as 23% in trading on Monday after President Trump announced his new Food and Drug Administration (FDA) chief, who happens to have ties to a business similar to Hims & Hers. In this video, Travis Hoium covers why this is important and why the stock is moving as fast as it is.*Stock prices used were end-of-day prices of Nov. 25, 2024. The vi ...

Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving. Bulls doubled their money with our Hims & Hers Health Inc (NYSE:HIMS) February 17 call recommendation in just over one week, so now is a good time to see how the trade played out. At the time of our recommendation on Nov. 17, HIMS had just nabbed an all-time high after a push above $30, which was three times its 2019 initial public offering (IPO) price. A sharp pullback followed that peak, which may have been exaggerated ...

Telehealth stock Hims & Hers Health Inc (NYSE:HIMS) nabbed an all-time high last week after a push above $30, which happens to be three times its 2019 initial public offering (IPO) price. The peak was followed by a sharp pullback, which may have been exaggerated by an unwinding of long positions associated with expiring November call open interest (OI) and delta-hedge selling related to heavy out-of-the-money OI in 11/22 through standard December options. There is plenty of support lingering below to captur ...

Is the food business the right business for Hims & Hers to be in?Hims & Hers (HIMS 0.79%) announced this week that it's getting into the nutrition business with bars and shakes. But are these the right products to add to a pharmaceutical business? Travis Hoium breaks down the news and how this fits into Hims & Hers' business in this video.*Stock prices used were end-of-day prices of Nov. 21, 2024. The video was published on Nov. 21, 2024. ...